The Emirates Drug Establishment has announced a major reduction in the retail prices of 168 pharmaceutical products across the UAE, delivering significant savings on medications used to treat chronic and life-threatening illnesses.
The revised pricing decision will officially take effect on May 30 and covers a broad range of treatments, including medicines for heart disease, diabetes, hypertension, cancer, stroke prevention, cholesterol disorders, respiratory illnesses, neurological conditions, mental health disorders and eye diseases.
Pharmacies across the UAE have already begun updating their pricing systems ahead of implementation, with reductions varying depending on the type of medication and therapeutic category.
According to the new pricing structure, discounts range from around 5 per cent to nearly 60 per cent for some of the country’s most expensive vital and biologic medicines.
Lower price for cholesterol medicine
One of the biggest reductions applies to Zocor 40mg, a cholesterol-lowering drug whose price has been reduced by approximately 59.5 per cent. Meanwhile, Xalatan, used to treat elevated eye pressure in glaucoma patients, recorded a price cut of more than 51 per cent.
Several high-cost cancer and biologic treatments also saw major reductions under the new decision. The lung cancer medication Alunbrig 180mg was reduced from Dh26,433 to Dh21,108, while the 90mg version dropped from Dh19,824 to Dh12,520. The 30mg dosage also saw a significant reduction, falling from Dh6,608 to Dh4,173.
In another major adjustment, Xeloda 150mg, commonly prescribed for breast, colon and rectal cancer, was reduced from Dh347 to Dh241.
The latest move is expected to provide substantial relief for patients requiring long-term treatment, particularly those dependent on expensive speciality medications and biologic therapies.